These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 31462403)

  • 21. The increasing threat of Pseudomonas aeruginosa high-risk clones.
    Oliver A; Mulet X; López-Causapé C; Juan C
    Drug Resist Updat; 2015; 21-22():41-59. PubMed ID: 26304792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational approach in the management of Pseudomonas aeruginosa infections.
    Bassetti M; Vena A; Russo A; Croxatto A; Calandra T; Guery B
    Curr Opin Infect Dis; 2018 Dec; 31(6):578-586. PubMed ID: 30299364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence-Based Treatment of
    Karruli A; Catalini C; D'Amore C; Foglia F; Mari F; Harxhi A; Galdiero M; Durante-Mangoni E
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Drugs for the Treatment of
    Losito AR; Raffaelli F; Del Giacomo P; Tumbarello M
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625223
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D; Castanheira M; Pfaller MA; Flamm RK
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 29. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
    Buonomo AR; Maraolo AE; Scotto R; Foggia M; Zappulo E; Congera P; Parente S; Gentile I
    Infection; 2020 Apr; 48(2):303-307. PubMed ID: 31981091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy.
    Ruiz-Garbajosa P; Cantón R
    Rev Esp Quimioter; 2017 Sep; 30 Suppl 1():8-12. PubMed ID: 28882007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
    García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
    Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 37. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.
    Fernandes M; Vira D; Medikonda R; Kumar N
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):315-22. PubMed ID: 26537122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Ma W; Li J; Wang D; Yu C; Sun S
    Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.